PharmaCorp Rx Inc. (TSXV:PCRX)
Canada · Delayed Price · Currency is CAD | Market Cap | 87.04M +48.4% |
| Revenue (ttm) | 27.41M +97.1% |
| Net Income | -1.07M |
| EPS | -0.01 |
| Shares Out | 174.08M |
| PE Ratio | n/a |
| Forward PE | 29.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.4950 |
| Previous Close | 0.5000 |
| Day's Range | 0.4950 - 0.5000 |
| 52-Week Range | 0.4000 - 0.5800 |
| Beta | -4.26 |
| Analysts | Strong Buy |
| Price Target | 0.67 (+34.0%) |
| Earnings Date | Aug 24, 2026 |
About PharmaCorp Rx
PharmaCorp Rx Inc. operates retail pharmacies under the PharmaChoice name in Canada. The company offers prescription services; front-of-store retail, such as convenience goods, over-the-counter medications, health products, and wellness items; custom compounding; specialized consultations; and lifestyle programs. PharmaCorp Rx Inc. was incorporated in 2021 and is headquartered in Saskatoon, Canada. [Read more]
Financial Performance
In 2025, PharmaCorp Rx's revenue was 20.89 million, an increase of 260.57% compared to the previous year's 5.79 million. Losses were -1.48 million, 46.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price target is $0.67, which is an increase of 34.00% from the latest price.
News
PharmaCorp Rx Earnings release: Q2 2026
PharmaCorp Rx released its Q2 2026 earnings on August 20, 2026, summarizing the period's financial results.
PharmaCorp Rx Registration statement: Q2 2026
PharmaCorp Rx filed a registration statement on August 20, 2026, providing details about a securities offering with the SEC.
PharmaCorp Rx Registration statement: Q2 2026
PharmaCorp Rx filed a registration statement on August 20, 2026, providing details about a securities offering with the SEC.
PharmaCorp Rx Slides: Investor presentation
PharmaCorp Rx has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
PharmaCorp Rx Registration statement: Q1 2026
PharmaCorp Rx filed a registration statement on June 1, 2026, providing details about a securities offering with the SEC.
PharmaCorp Rx Registration statement: Q1 2026
PharmaCorp Rx filed a registration statement on June 1, 2026, providing details about a securities offering with the SEC.
PharmaCorp Rx Earnings release: Q1 2026
PharmaCorp Rx released its Q1 2026 earnings on June 1, 2026, summarizing the period's financial results.
PharmaCorp Rx Slides: Investor presentation
PharmaCorp Rx has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
PharmaCorp Rx Earnings release: Q4 2025
PharmaCorp Rx released its Q4 2025 earnings on April 29, 2026, summarizing the period's financial results.
PharmaCorp Rx Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
At the 2026 Bloom Burton Healthcare Investor Conference, a pharmacy roll-up firm detailed its exclusive acquisition pipeline, flexible exit options for owners, and focus on operational stability and top-line growth. Recent capital raised will fund further expansion and team growth.
PharmaCorp Rx Earnings release: Q3 2025
PharmaCorp Rx released its Q3 2025 earnings on November 27, 2025, summarizing the period's financial results.
PharmaCorp Rx Slides: Q3 2025
PharmaCorp Rx has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 27, 2025.